Asthma is a common chronic disease characterized by airway inflammation and
bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects
of airway inflammation in patients with asthma.
The study will be conducted on 14 adult steroid naive patients with asthma. Patients with
qualifying pulmonary function testing values will be eligible for enrollment. Enrolled
subjects will be treated with rosiglitazone orally at 2mg dose for 4 weeks. Patients will be
reassessed and dosing will increase in 4 week increments up to 8mg.